QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
Helping hospital and emergency room customers respond to the critical demand for enhanced opioid testing
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410125315/en/
QuidelOrtho Vitros® XT 7600 Integrated System (Photo: Business Wire)
According to the
“This assay transforms laboratory efficiency by integrating fentanyl testing with existing protocols to eliminate the need for external screening tests, and consolidates a lab’s drugs-of-abuse panel into a singular, streamlined system, reducing intervention time and ultimately helping to save lives,” said
Ninety percent of fentanyl is excreted as norfentanyl, which is a synthetic opioid and is not detected on standard drug screening.1 The ARK™ Fentanyl II Assay provides preliminary analytical test results by detecting this major metabolite, reducing the risk of false negatives. As part of QuidelOrtho’s Vitros systems’ menu of assays, the test offers clinical fentanyl testing for hospitals and emergency departments, providing an effective approach to preliminary urine drug testing.
Drug test results obtained in emergency departments play a crucial role in addressing unique hospital challenges. When patients test positive for opioids on a standard drug test, they’re usually directed to drug treatment programs. However, these standard tests fail to identify synthetic opioids, such as fentanyl.1 Without specifically testing for fentanyl, instances of fentanyl exposure might be disregarded, potentially leading to missed opportunities for life-saving interventions like administering naloxone, an opioid overdose reversal medication.
“Substance use is always changing, and medicine must change to address the problems our patients face,” said Dr.
-
Center for Disease Control and Prevention . Opioid overdose. AccessedMarch 28, 2024 . https://www.cdc.gov/drugoverdose/deaths/opioid-overdose.html -
CESAR Center for Substance Abuse ,Addiction and Health Research . UMD-led system shows success in helping hospitals understand fentanyl use in their communities. AccessedMarch 29, 2024 . https://cesar.umd.edu/feature/umd-led-system-shows-success-helping-hospitals-understand-fentanyl-use-their-communities
Resources:
-
Global MPA Website – MicroTip Partnership Assays (MPAs) |
QuidelOrtho
About
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation,
For more information, please visit www.quidelortho.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410125315/en/
Investor Contact:
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Senior Director, Corporate Communications
media@QuidelOrtho.com
Source: